The Cobas® EGFR Mutation Test v2 assay

Future Oncol. 2016 Feb;12(4):451-2. doi: 10.2217/fon.15.311. Epub 2016 Feb 3.

Abstract

Paul Brown speaks to Gemma Westcott, Commissioning Editor: Paul Brown has served as the Head of Roche Molecular Diagnostics at Roche Diagnostics Corporation since February 2010 having previously held a variety of positions within Roche Pharma. After completing his doctorate in organic chemistry he was awarded a post-doctoral fellowship at the California Institute of Technology in Pasadena, CA, USA, but soon returned to his native UK to join Roche Pharma Research. Paul's first post within Roche was as group leader, doing drug discovery and making new small molecule drugs, but later moved into the business part of the company. Since then, he has enjoyed roles such as lifecycle leader for brands such as Tamiflu(®) and Xenical, vice president of sales and marketing of the pharmaceutical division and most recently general manager of Roche Pharma, Sweden.

Keywords: Cobas® EGFR Mutation Test v2; in vitro diagnostics; lung cancer; oncology.

Publication types

  • Interview

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / diagnosis
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics*
  • Genetic Testing / methods*
  • Genetic Testing / standards
  • Humans
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Molecular Targeted Therapy
  • Mutation*
  • Patient Selection
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Reagent Kits, Diagnostic / supply & distribution
  • Research

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Reagent Kits, Diagnostic
  • ErbB Receptors